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Abstract
The principles of the 3Rs, Replacement, Reduction and Refinement, are being increasingly incorporated into legislations,
guidelines and practice of animal experiments in order to safeguard animal welfare. In the present study we have studied
the systematic application of 3R principles to toxicological research in the pharmaceutical industry, with particular focus on
achieving reductions in animal numbers used in regulatory and investigatory in vivo studies. The work also details major
factors influencing these reductions including the conception of ideas, cross-departmental working and acceptance into the
work process. Data from 36 reduction projects were collected retrospectively from work between 2006 and 2010.
Substantial reduction in animal use was achieved by different strategies, including improved study design, method
development and project coordination. Major animal savings were shown in both regulatory and investigative safety
studies. If a similar (i.e. 53%) reduction had been achieved simultaneously within the twelve largest pharmaceutical
companies, the equivalent reduction world-wide would be about 150,000 rats annually. The results point at the importance
of a strong 3R culture, with scientific engagement, collaboration and a responsive management being vital components. A
strong commitment in leadership for the 3R is recommended to be translated into cross-department and inter-profession
involvement in projects for innovation, validation and implementation. Synergies between all the three Rs are observed and
conclude that in silico-, in vitro- and in vivo-methods all hold the potential for applying the reduction R and should be
consequently coordinated at a strategic level.
Citation: Törnqvist E, Annas A, Granath B, Jalkesten E, Cotgreave I, et al. (2014) Strategic Focus on 3R Principles Reveals Major Reductions in the Use of Animals in
Pharmaceutical Toxicity Testing. PLoS ONE 9(7): e101638. doi:10.1371/journal.pone.0101638
Editor: Kathrin Eller, Medical University of Graz, Austria
Received March 14, 2014; Accepted June 9, 2014; Published July 23, 2014
Copyright:  2014 Törnqvist et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the paper.
Funding: Funding provided by Swedish Research Council (www.vr.se) No.C0186901 and Institute of Environmental Medicine (ki.se/imm). The funders had no role
in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: Elin Törnqvist, Anita Annas, Britta Granath, Elisabeth Jalkesten and Ian Cotgreave were previously employed by AstraZeneca R & D. The
data used in this study comes from a former AstraZeneca Unit. There are no patents, products in development or marketed products to declare. This does not
alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.
* Email: mattias.oberg@ki.se
Introduction
The 3Rs, defined as Replacement, Reduction and Refinement,
are fundamental principles for driving ethical research, testing and
education using animals. The principles were proposed by Russel
and Burch in 1959 [1], and since have been widely accepted and
adapted to modern society in general and to science research in
particular, as described at the Sheringham workshop 1995 [2] and
in Bologna 1999 [3]. The 3Rs are currently incorporated as a key
concept for humane use of animals in research into various
important legislations, for instance in the European Union (EU)
[4], Brazil [5] and Japan [6]. They are also implicit in the
respective Animal Welfare Acts in the United States [7], in China
[8] and in India [9,10]. The principles of the 3Rs are also well
integrated into international guidelines for toxicity testing, such as
the guidelines developed by the Organization for Economic Co-
operation and Development [11], and into regulatory test
guidelines applicable for safety assessments/toxicity evaluations
for chemicals [12,13], pesticides [14], cosmetics [15] and
pharmaceuticals [16]. National 3R advisory boards, or 3R centers,
have been active in Canada since 1968 [17], in Australia and New
Zealand since 1987 [18] and in UK since 2004 [19], each tasked
with funding 3R research, performing surveys on views in the area
of animal ethics and promoting an open dialogue about research
on animals. The newly adopted EU directive on the protection of
animals used for scientific purposes demands of members of the
Union to increase collaboration in the 3Rs, which puts a pressure
on the member states to establish national 3R centers [4]. Several
3R centers have been recently started, such as FICAM in Finland
in 2004 [20], and the Netherlands Knowledge Centre on
Alternatives to animal use (NKCA) in 2010 [21].
Although officially embraced in various legislations and
guidelines, and despite strong private and official initiatives, the
principles of the 3Rs are not yet fully incorporated into the
everyday animal-based research. The discrepancy between the
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3Rs vision and general, everyday practices at both regulatory
authorities and research units in the industry or academia is well
illustrated in public surveys. In a survey of Canadian researchers’
views on the 3Rs, the respondents will to embrace the 3Rs was
recorded, but there was a clear lack of knowledge in how to
transform the 3R principles into practice [22]. Further, the
responding researchers did not see replacement of animals in
research as achievable or realistic. There was also an attitude that
the 3Rs not only would disturb the research process in terms of
time and cost, but would also compromise research data, primarily
due to loss of statistical significance when applying the reduction
R. The need for increased efforts and plans for continuous
education in animal ethics is pointed out in a survey of members of
the Canadian Institutional Animal Care and Use Committees
[23]. In ‘‘Views on the 3Rs’’, a survey report from 2012 by the
Department for Business, Innovation and Skills in the United
Kingdom, scientists and animal care staff were asked when during
the research process the 3Rs was considered [24]. As many as 95%
of the respondents considered the 3Rs when commencing their
projects, dropping to 50% during execution of the work to about
25% when presenting data at conferences or meetings. This trend
clearly shows that opportunities for cooperation and sharing
information and best practice are not being fully exploited. In
addition, an increase of animal use in research in general, and a
shortcoming in the efforts to implement the 3Rs, especially
reduction, is illustrated by the increase in the percentage of articles
reporting animal use in four high ranking journals between the
years of 1983 and 2007 [25].
Today there is no globally standardized way of reporting on any
of the 3R principles, and legislation and reporting of animal use in
relation to the 3Rs varies strongly between different countries.
This presents difficulties in obtaining an overview of the progress
and implementations of the 3Rs regionally, nationally and
globally. In advance of this, visions and measurable goals for
driving 3R-based improvements in biomedical research differ
between both individual countries and different areas of research,
and there is urgent need for a more structural and effective
exchange of method developments, databases and best-practice
examples. There is also a need to separate the 3Rs in order to
assimilate academic and practical expertise for each R individually
[26], as well as a need for greater academic focus on the 3R
research, in order to increase the status of the research area [27].
According to European commission data from 2011, about 11.5
million laboratory animals were used annually in the European
Union, and 8.75% of these animals were used for toxicological
evaluations and safety assessments, with every second animal used
to fulfill legislative demands [28]. Many 3R initiatives have been
developed in toxicological research, both at the research and
legislative levels. One concerted paradigm is in the field of toxicity
testing of cosmetics, where the 3R vision was imprinted by
implementation of the regulation on cosmetic products, enhancing
and supporting the continuous work with establishment and
validation of alternative methods [15]. More than 80 methods
have been validated, of which 50 are in vitro tests, 10 use isolated
organs and the remainder are refined in vivo methods regarded as
more humane to the animals [29]. A recent example of a research
initiative within the field of testing of cosmetics is the ‘‘Safety
Evaluation Ultimately Replacing Animal Testing’’ (SEURAT-1)
that cluster the research efforts of over 70 European universities,
public research institutes and companies and focuses on the
complex area of repeated dose toxicity [30]. These efforts in
toxicology may present great opportunities for cross-fertilizing
efforts into other areas of biomedical research, where 60% of the
animals utilized in the EU find application, and where little or no
concerted effort is being applied to develop 3R-based research
paradigms.
In contrast to these efforts in the public research forum, little
information is available from application of 3R principles within
industrial research. In the present study we display various
methods to implement 3R thinking into the core operating
practices of a multi-national pharmaceutical company, from the
perspective of toxicity testing for human risk assessment. Data was
obtained from the Safety Assessment Unit at AstraZeneca R&D,
Sweden, whose operating model was focused on performing
preclinical regulatory and investigative toxicity testing of future
medicines. In a retrospective review, animal use data from fully
implemented 3R projects were collected over a 5 year implemen-
tation period from 2006 to 2010, and the analysis combined with
detailed mapping of how, where and why these 3R ideas occurred
and how they were implemented. The overall aim of the present
study was to explore strategies for future ways of working with the
3Rs locally and globally within a research organization performing
investigative and regulatory toxicity studies. In addition, the aim
was to study the importance of involvement and empowerment of
all employees at different levels of the organization to consider the
3Rs in their everyday work. The results reveal achievement of
considerable reductions in animal uses, and the major factors
which dictate this in a large commercial organization. The results
are also discussed in terms of propagation of best-practice to other
organizations in order to maximize impact on animal welfare.
Materials and Methods
All data were obtained from the Safety Assessment Research
Unit at AstraZeneca in Södertälje, Sweden. At the time of this
retrospective study the unit comprised of eight departments
(Figure 1), including 300 staff (scientists, technicians, veterinarians,
quality assurance experts and managers). The research unit
performed preclinical toxicity studies and evaluations according to
regulatory guidelines, as well as carrying out studies on investi-
gative basis, in order to support the company’s various drug
projects in predicting potential side effects before clinical trials in
man. During 2009, the unit completed over 300 scientific
preclinical safety assessment reports of which one third was
performed in vitro and two thirds in vivo. Test species for in vivo
studies included the rat, mouse, rabbit and dog. All animals were
acclimatized before start of study and test substances were
administered orally, intravenously, subcutaneously or via inhala-
tion depending on anticipated future route of administration in
man. Toxicological evaluations were based on in vivo findings
such as blood and urine samples, and on toxicological findings at
necropsy. Humane endpoints were decided for each study as well
as method of sacrifice appropriate for the species used. All species
were included in the systematic work with 3R described below. All
in vivo research was performed in a Good Laboratory Practice
(GLP) facility in accordance with national legislations for research
on animals and the EU directive on the protection of animals used
for scientific purposes (86/609/EEC), and was ethically approved
by an external ethical committee (the Ethical Committee of
Animal Experiments in Stockholm). Lean Sigma process optimi-
zation was also operative throughout the test period. The unit was
closed by December 2012.
In order to review the outcome of different 3R projects aimed at
reduction, all reduction improvements implemented from 2006 to
2010 at the Safety Assessment Research Unit were collected
retrospectively. Reduction was defined as ’’any methods for
obtaining comparable levels of information from the use of fewer
animals, or for obtaining more information from the same number
Strategies for Reduction of Animal Use in Toxicity Testing
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of animals’’. This definition is in accordance with the widely
accepted conclusions and recommendations of the Sheringham
workshop from 1995 [2]. Each reduction project included had
been thoroughly discussed and validated before management
approval and implementation.
All collected reduction improvements implemented were
categorized according to three different categories:
(1) ‘‘Improved study design’’, defined as projects resulting in a
reduction of animal use either after decreasing the number of
animals in test groups or excluding test groups in a certain study
type, or by excluding certain parameters/study types in series of
studies. The decisions to change the study design were based on
experience, historical data or increased knowledge, and conse-
quently resulted in a scientifically more optimized study design as
well as a reduction of animal use.
(2) ‘‘Method development’’, defined as projects resulting in a
reduction of animal use achieved by introduction of more sensitive
assays/techniques, facilitating smaller amounts of body fluids or
tissues for analyses and optimizing delivery of test parameters from
the same animal instead of using individual animals for each
parameter. This results both in more scientific information per
animal and in a reduction of number of animals needed in each
test group. Other methods developed to reduce the number of
animals used were in vitro assays for screening to exclude
compounds before testing in vivo, as well as in silico methods
enabling more effective processing of research data.
(3) ‘‘Coordination’’, defined as projects resulting in a reduction
of animal use achieved by increased collaboration and commu-
nication between various contributing departments. This enabled
combining different scientific aims from separate areas of
toxicology testing in one study, and the sharing of control animals
when applicable. Reduction by coordination was also achieved by
combining in vivo and in vitro studies instead of using separate
animals for in vitro/ex vivo testing, as well as by biobanking
samples for future use. Combining such studies could be planned
in advance by increased communication and collaboration
between departments.
Before and after the implementation of the new procedure, the
number of animals used (per study and/or per year) was estimated
by the project owner for each reduction project. Collated data per
year were derived and a measure of overall reduction per year
based on animal use and number of toxicity studies during 2009
for each species. For some projects the actual reduction in
numbers was imprecise in nature due either to irregular use of the
study, or to the technique described, or in the extent the future
need and use of a certain technique/process, particularly in the
case of the preclinical biobank. The overall reduction is therefore
likely to be slightly underestimated.
Each reduction project was linked to departmental ownership of
the project in order to map and analyze involvement and
engagement into the 3R work at the Safety Assessment Research
Unit. In cases where project ownership was shared between two or
more departments, all departments involved were recorded.
General 3R-projects aiming at high-level organization of different
parts of the 3R work at the unit were also listed.
Results
A total of 36 implemented reduction projects were identified for
the period 2006 to 2010. Of these, 32 were implemented on rat
studies (Tables 1–3) and four were dog-specific (not included in
tables). Several of the identified rat-projects were also applicable
for other species, i.e. mice, rabbits and dogs.
Projects were related to either improvement of study design,
method development or coordination. The improved study designs
(Table 1) resulted in a total estimated annual animal reduction of
1151 rats, which equates to 20% of the total estimated reduction.
Half of this reduction was achieved by excluding birth groups from
dose-range finding studies in reproduction toxicity studies (Project
No. 1). The introduction of new dosing-routines (No. 5 and 6) was
the second most important reduction strategy, reducing the
estimated number of rats by 280 annually in oral and intravenous
micronucleus tests. Improving the study design so that two
separate studies could be merged into one (No. 2 and 3) was the
Figure 1. Schematic illustration of the Safety Assessment Research Unit at AstraZeneca, Södertälje. The unit comprised eight
departments and performed preclinical toxicity studies and evaluations to support the company’s various drug projects to predict potential side
effects before e.g. clinical trials in man.
doi:10.1371/journal.pone.0101638.g001
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third most important strategy, reducing the annual use of rats by
253. Dose-setting for 6-months inhalation toxicity studies were
previously based on a 3-month study. An evaluation showed that
this study could be excluded and the dose-setting based on a 1-
month study, reducing the number of animals with 354 to 236
(No. 4). The annual impact of this study design improvement was
not assessed since the project was implemented at the very end of
the investigated period. In one project (No. 7) the number of
animals was reduced due to smaller group sizes, a result of high
pregnancy rates at the facility. Finally, two projects (No. 8 and 9)
reduced the number of animals by introducing historical data for
control and shared control groups. It was, however, not possible to
estimate the annual impact of all these projects within the time-
frame of the evaluation.
Method developments had a substantial impact on reduction of
laboratory animals and resulted in an estimated reduction by
3430–4378 rats, more than two thirds of the total estimated annual
animal reductions achieved at the unit over the test period
(Table 2). Development of computer programs (Project no. 10)
and new in vitro methods (No. 11, 19 and 20) resulted in 67–
100% reduction in use of animals, corresponding to a reduction of
at least 340 rats every year. The most important method
improvements, in terms of reduced number of animals, were the
development of new blood sampling techniques. For example,
micro sampling enabled fewer satellite animals used for toxicoki-
netic evaluations. When this and other new blood sampling
routines were introduced, the estimated use of rats dropped by
approximately 3500 rats annually. A minor reduction was also
achieved by new pathological methods (No. 12). Reduction
projects involving continuous development of methods for
biomarkers (No. 21) were not quantifiable in terms of number of
animals, but indicate a movement forward with future possibilities
for both reduction and replacement of animal use.
Eleven reduction projects were related to coordination of the
work with laboratory animals (Table 3). Annual reduction in use of
rats achieved by coordination was estimated to 652 animals, which








1. Dose-range finding studies in reproduction toxicity studies. Birth groups excluded from standard design and
only included if birth issues are indicated. Reduction from 66 to 48 females and from 180 to 0 puppies per study.
3 246 to 48 594
(80%)
2. Combining studies of embryo-fetal development and female fertility. Evaluation in one combined study instead
of performing two separate studies by adjusting dosing, mating and necropsy to fit for both scientific purposes.
2 160 to 80 160
(50%)
3. Combining the micronucleus test and the comet assay by adjusting dosing and necropsy to fit for both
scientific purposes. Reduction from 63 rats (28 rats in the micronucleus test, and 45 rats in the
comet assay) to 32 rats per combined study.
3 63 to 32 93
(49%)
4. Optimized project design for inhalation projects. Based on experience and scientific evaluation of
inhalation studies, it was concluded that the results from the 1-month study could be dose-setting
for the 6-month study, hence the 3-month study could be excluded.
NA 354 to 236 a)
(33%)
5. New dosing routine for oral micronucleus tests. Evaluation after single dosing was excluded and
two dose regimen was adopted as standard, enabling detection of micronucleus developed within
24 and/or 48 hours after dosing in the same animal.
10 42 to 28 140
(33%)
6. New dosing routine for intraveneous micronucleus tests. Evaluation after single dosing was excluded
and two dose regimen was adopted as standard, enabling detection of micronucleus developed within
24 and/or 48 hours after dosing in the same animal.
10 42 to 28 140
(33%)
7. Fewer animals in the embryo-fetal development studies. Change of group size from 22 to 20 females
per group due to documented high pregnancy rate at the facility. Reduction from 88 to 80 rats per study.
(Also applicable for rabbits)
3 88 to 80 24
(9%)
8. Optimized control groups in investigative pathology toxicity studies. Control groups are reduced by
50% by using historical data with background variation.
NA b) b)
9. Shared control groups in investigative studies. The same control group was used for more than one
scientific issue when scientifically motivated. (Applicable for any species)
NA b) b)
Total Estimated Annual Animal Reduction 1 151
NA = Not analysed
a) Not possible to estimate as the routine was implemented just before the end of the investigated period.
b) Not possible to estimate as the design and number of investigative studies varies a lot between years. To be evaluated after 2–3 years.
doi:10.1371/journal.pone.0101638.t001
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equals 11% of the total estimated reduction at the safety
assessment research unit. Five of the projects (Projects No. 22
and 24–27) were achieved by coordination between different
research areas at the Safety Assessment Research Unit, which
resulted in increased scientific data from each animal used.
Coordinated purchase and ordering of animals (No. 23) resulted in
a reduction in use of ‘‘extra’’ rats by 50%. Several reduction
projects in the category of coordination were not possible to
quantitatively evaluate, including the coordination of controls with
the same vehicle (No. 28); establishment of a preclinical biobank
(No. 29); biobank for control animal tissues (No. 30), studies of
biomarkers in regulatory toxicity testing to avoid separate in vivo
studies (No. 31); and introduction of routines for thorough
interdepartmental discussions to avoid unnecessary use of labora-
tory animals (No. 32).
Overall, as a result of the 32 implemented reduction projects the
unit was able to increase the number of regulatory toxicity studies,
mainly with long-term exposure, with 79%, from 14 studies in








10. New computer program for safety pharmacology parameters in dogs. The program enabled inclusion of
respiratory tests into telemetry studies in dogs. Hence, separate respiratory studies in rats could be excluded.
4 40 to 0 160
(100%)
11. New in vitro assays based on in vivo results. Screening proposed drug candidates without in vivo studies
in drug projects with anticipated side effects such as gallbladder or hepatic toxicity. (applicable to all species)
3 60 to 0 180
(100%)
12. Combining 3 pathological examinations. Using one rat instead of three in a 3D-reconstruction of the heart. NA 3 to 1 a)
(67%)
13. New blood sampling routines in inhalation toxicity studies. Previously, blood sampling for toxicokinetics
was performed via heart puncture at euthanasia as large blood volumes were needed for analytical determination.





14. Micro sampling in dose-range finding studies for further reproduction toxicity testing. No extra
groups for toxicokinetics evaluation
3 48 to 24 72
(50%)
15. Micro sampling in the test for physical dependence, safety pharmacology. No extra groups with 4–8
animals for toxicokinetic evaluation. Reduction from 48–64 to 32 animals per study.d
3 48–64 to 32 48–96
(33–50%)
16. New method for blood sampling for coagulation evaluations. Sampling via tongue vein instead of





17. Micro sampling for regulatory toxicity studies with oral, subcutaneous or intravenous exposure.
Reduced blood volumes needed for kinetic evaluations in studies longer than 14 days. Reduced number
of extra animals. Reduction from 136 to 100 rats per study. (applicable also in mice)
15 136 to 100 540
(26%)
18. New blood sampling routines in inhalation toxicity studies. Further development of project No. 13,
a new analysis method for kinetics enabled even lower sample volume (from 500 mL to 300 mL)
and consequently reduced number of extra animals for blood sampling.
15 136 to 118 270
(13%)
19. New in vitro screening for testing of bone marrow toxicity. In vitro screening in three steps: if tested
positive in in vitro mouse cell line test, the substance is tested ex vivo in human cell culture. If still positive,
tested on bone marrow from animals euthanized after exposure for the substance. Reduction as a result
of fewer drug candidates to be tested in vivo.
NA a) a)
20. New in vitro model for liver toxicity. A bioreactor that simulates human liver function aiming at
better simulation of the human physiology and at avoiding use of primary animal liver cells.
NA b) b)
21. Continuously discovering new biomarkers for safety assessments. Results in better diagnostics,
more information, more proper decisions and evaluations which may result in minimized group
sizes and optimized study design and early decisions of toxicity and risk of side effects in humans and
by that avoiding ‘‘unnecessary’’ research in animals.
NA c) c)
Total estimated annual animal reduction 3430–4378
NA = Not analysed
a) Not possible to estimate as the test/study is performed when requested and this varies substantially between years.
b) Not possible to estimate the effects on reduction of animal use or replacement of animal studies today.
c) Not possible to estimate as the number of biomarker studies and study design varies depending on present drug projects and safety assessment issues. Probably a
reduction of more than one hundred animals per year. To be evaluated after 2–3 years.
d) Possible risk for interference with observations of clinical signs is addressed and during scientifically investigation and evaluation before implementing the method as
default.
doi:10.1371/journal.pone.0101638.t002
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2006 to 25 studies in 2010 (Figure 2). An even higher increase was
found for investigative studies. This type of shorter duration
studies almost doubled, from 53 studies in 2006 to 105 studies in
2010.
Several of the identified reduction rat-projects were also
implemented for the other species used at the unit, with significant
reduction of the number of animals as a result (indicated in the
footnote of tables 1–3); mice (9 projects); rabbits (7 projects); and
dogs (6 projects). Moreover, four projects were implemented only
for dogs, including two projects of optimized study design and two
projects with new routines related to telemetry during safety
pharmacology studies, reducing the annual use of dogs with 130.
Based on all studies performed at the unit 2009, the actual number
of animals was compared with the number of animals that would
have been used per study if none of the reduction projects would
have been performed. The implemented reduction projects
resulted in an estimated reduction (only including projects with
quantifiable reduction) of animal use in all species ranging from
8% in rabbits to 53% in rats (Figure 3). Assuming no reduction
strategy implemented, the actual number of animals would have
been significantly higher; +5707 rats, +324 mice, +24 rabbits and
+130 dogs, a total saving of over 6000 animals every year.
The organizational analysis showed that initiative and imple-
mentation of the reduction projects was organized from all eight
departments at the unit (Figure 4a). The three different reduction
categories were scattered over the different departments
(Figure 4a). One of eleven study design improvements were
initiated cross departments, whereas a larger proportion of projects
related to method development (5/14) and coordination (4/11)
were initiated cross-departmentally. Single department initiatives
came both from the expert departments upstream of the animal
department (11 projects) and the specialist departments down-
stream of the animal department (11 projects). Few single
department initiatives were initiated from the project leader and








22. Combining micronucleus studies and regulatory 1-month toxicity or shorter early high dose studies.
Bone marrow sampling at necropsy when applicable. Reduction of animal use in separate micronucleus
studies (28 animals per study).f
NA 28 to 0 a)
(100%)
23. Coordination of ordering of animals. Better communication and more homogenous size of delivered animals
reduced the number of animals from 10 to 5% extra. Reduction from 12 to 6 per study. (also applicable for mice)
35 12 to 6 210
(50%)
24. Combining 3 scientific evaluations in lung pathology examinations. BAL, organ weight, and
histopathology were examined in one instead of two animals.




25. Combining three scientific evaluations in investigative studies in safety pharmacology. 1 168 to 102 66
(39%)
26. Including male fertility testing in the 6 months regulatory toxicity study. 90 rats in the six months
study and 160 rats in male fertility studies were reduced to 90 rats plus 80 females to be mated.
2 250 to 170 160
(32%)
27. Combining behavior/physiological tests and inhalation toxicity tests. Including Irwin tests in
inhalation studies. Separate inhalation: 98 rats per inhalation study and 36 separate rats for Irwin
test were reduced to 118 per combined study.
6 154 to 118 216
(23%)
28. Using the same vehicle control. The vehicle control was used for several test substances when applicable. NA a) a)
29. Setup of a Preclinical Biobank. Archive samples collected from all studies to avoid repeated in vivo studies
for possible future need of additional/completing information such as biomarkers. (applicable for all species)
NA b) b)
30. Setup of a Biobank with control samples. A biobank for future use at method development or
validation. (applicable for all apecies)
NA c) c)
31. Including biomarker studies in regulatory toxicity. By receiving tissue and fluids from animals in ordinary
test groups when applicable. (applicable for all species)
NA d) d)
32. New routines for thorough discussions. Scientist from different fields/departments discuss before
start of study in order to maximize the scientific value and reduce unnecessary use of animals.
(applicable for all species)
NA e) e)
Total estimated annual animal reduction 652
NA = Not analysed
a) Not possible to estimate as the number of studies varies between years. To be evaluated after 2–3 years.
b) Not possible to estimate as the number of investigative studies varies between years. Probably an annual reduction of more than hundred rats. To be evaluated after
2–3 years.
c) Not possible to estimate as the number of method development and/or validation studies varies between years. Probably an annual reduction of more than one
hundred rats. To be evaluated after 2–3 years.
d) Not possible to estimate as the number of biomarker studies varies depending on present drug projects and safety assessment issues. Probably an annual reduction
of more than one hundred rats. To be evaluated after 2–3 years.
e) Not possible to estimate as the projects vary in nature.
f) Risk for too low exposure for micronucleus evaluation is addressed and during scientifically investigation and validation before implementation as default.
doi:10.1371/journal.pone.0101638.t003
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the animal department. However, one or both of these two
departments were involved in nine of the ten cross-departmental
projects (Figure 4b). One fourth (10/36) of the reduction projects
was initiated by two or more of the departments at the unit
(Figure 4a).
Discussion
Three strategies for reduction
By detailed polling and analysis of a retrospective survey over a
five year period and by collating projects which achieved
reductions in animal use either by (1) improved study design, (2)
method development or (3) coordination, each of the three
categories were shown to contribute significantly to the overall
reductions achieved. We identified 36 reduction projects, of which
32 were implemented on the use of rats (Tables 1–3). Several of
the rat-projects were also implemented on the use of other test
species (mice, rabbits and dogs), whereas four projects were only
implemented on dogs (data not shown). All three strategies were
equally common. However, in terms of differential effects on
reductions in the use of rats, 20% was due to improved study
design, 68% of the total reduction was achieved due to method
development and 12% due to new projects related to tactical
coordination.
A main strategy to achieve reduction of the number of animals
was through modification of the study design (Table 1). When
implemented in studies with large number of animals, such as the
reproduction toxicity studies, the impact was shown to be
substantial. Reductions related to study design were also achieved
by adjusting schedules for dosing, mating and necropsy, to fit the
purposes of two separate studies in to one study. The number of
control animals was also reduced by using historical data or by
using the same control group for several investigative issues.
Without a systematic organizational structure for 3R including all
departments, as discussed below, this type of coordinated design
shift would have been impossible. Moreover, a minor reduction
was achieved by the change of group size in embryo-fetal
development studies due to documented high pregnancy rate at
the facility. The latter project is a strong example of a synergy
between the two Rs for refinement and reduction.
Method development was shown to be the most efficient
strategy for achievement of reduction in animal use (Table 2). One
of the most influential improvements was the introduction of new
blood micro-sampling methods. This innovative method for
reduction was based on previous improvements in analytical
abilities, and clearly shows the interaction between frontier
technical developments, not only in replacement, but also in the
application of the reduction R. Other key method developments
were related to introduction of new in vitro and in silico methods
for screening in a tiered approach during the ‘‘design-make-test-
analyse cycle’’ and lead optimization procedures, and prior to in
vivo testing. Introduction of in vitro and in silico methods is often
categorized as an example of replacement rather than reduction.
However, the present study gives examples of how non animal
methods can be used to guide the subsequent in vivo studies in a
Figure 2. Total number of rats used in toxicity studies at the Safety Assessment Research Unit (black line) and total number of
reported regulatory toxicity studies, one month or longer (black bars) and shorter investigative toxicity/mechanistic studies (grey
bars) during the years 2006–2010.
doi:10.1371/journal.pone.0101638.g002
Figure 3. Estimated reduction in number of animals used in
toxicity studies at Safety Assessment Research Unit. Actual
number of animals used in 2009 (black bars) compared with the
estimated number of animals if no reduction projects would have been
implemented (grey bars).
doi:10.1371/journal.pone.0101638.g003
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reduction direction. Based on these observations, it is therefore
recommended to coordinate the development of new in vitro
methods with the workings of the in vivo departments, and to
further build on a paradigm where in silico-, in vitro- and in vivo-
methods all hold the potential for applying the reduction R.
In addition to study design and method improvements, eleven
projects used tactical coordination as a mean for reduction
(Table 3). In comparison to the other two strategies, the
quantifiable impact by better project coordination was more
uncertain. Two projects related to the combination of studies were
not possible to evaluate in quantitative terms within the short time-
frame of this study, since the number of studies vary substantially
between years. However, combining tests related to different
departments and minimizing the purchase of ‘‘extra’’ animals
reduced the number of rats in quantifiably terms. Finally, four
projects were related to new approaches for cooperation within the
unit, such as establishment of bio-banks and systematic search for
biomarkers. Here it is estimated that savings would be another 5–
10% (250–500) annually. The active coordination within a
research unit represents a major in-road in the application of 3R
principles into the central risk assessment strategies of the
pharmaceutical industry, particularly in the area of regulatory,
repeated dose, systemic toxicity testing. A pre-clinical bio-bank
may for example hold the potential of new research on biomarkers
and validation of new test methods.
The present data shows a two-fold increase of pivotal safety
assessment support to the drug projects at the company, whilst the
number of rats used remained at unchanged levels (Figure 2). The
research unit obtained more information from the same number of
animal used, which demonstrates that the systematic 3R work at
the research unit has resulted in a reduction, according to the
definition. For example, toxicokinetic data was achieved from
individual animals rather than from satellite animals. The highest
reduction was achieved in the use of rats, the most common
laboratory animal at the facility (Figure 3). Several projects were
also applicable for other species and the reduction was also
significant for mice, rabbits and dogs. These results indicate that
the identified strategies for reduction via new study designs,
methods and coordination have an inter-species relevance.
Process management
There is a considerable pressure from society on the area of
biomedical research to apply 3R principles to research involving
animal experimentation. Central to this is the reduction in animal
use which could have a major impact in multiple areas of research.
Although officially embraced in various legislations and guidelines,
the discrepancy between society’s 3Rs vision and practices is well
illustrated in public surveys [22–24]. There is a documented fear
among researchers that applying the reduction R would compro-
mise the informative value of the study. In highly regulated areas,
like the pharmaceutical industry, statements as ‘‘without changing
the OECD guidelines it is almost impossible to reduce the number of
animals in regulatory toxicity studies’’ are not uncommon. The
importance of fostering a culture of communication and collab-
oration in the use of animals in biomedical research was explored
by tracking the project to the initiating department. The initiative
and implementation of the reduction projects was organized from
all departments at the lab (Figure 4), indicating that the 3R
thinking and practice were integrated in everyday work at all levels
in the studied organization. In more than one out of four projects
(10/36), the initiative and project steering was cross departmental,
showing that the 3R culture had effectively infiltered the whole
organization. Here, management support, combined with techni-
cal advances, e.g. new assays/methods, increased level of
knowledge and development of computer programs, were all key
factors enabling the staff to go from idea to implementation. In
terms of key management activities, the establishment of cross-
departmental teams for 3R-overview and support of the ethical
applications and a new strategy for internal and external
communication related to 3R were vital components in establish
the 3R culture. According to the initiators of the different projects,
this 3R working culture allowed ideas to be expressed, tested and
evaluated considering both excellent science as well as ethical and
enduring developments. At an organizational level, the 3R work at
the research unit was supported by structured continuous
improvement steering with mutual vision, goals and strict follow-
ups, according to the Lean Sigma approach. Another important
factor to increase 3R awareness was the involvement of all working
categories within the organization. Thus, it was essential to include
animal technicians in the research process, to give them more
responsibilities in experimental procedures and authority to report
observations and research data. The increased motivation and
confidence of this working category was indicated by the highest
proportional involvement in cross-departmental 3R projects at the
unit (Figure 4).
It is evident from this study that the organizational culture,
defined as a pattern of basic assumptions that help to form a
common way for group members to understand and solve
problems, is equally or more important than the implementation
of the 3R principles into legal regulations and national/
international guidelines. This conclusion is also supported by
previous work [31]. A lack of organizational 3R culture can be
seen as a concern among researchers that application of the 3Rs
could risk the scientific quality and increase costs [22], or that
animal pain and distress is inversely related to reduction of animals
[32]. In the present study, we show that these concerns are not
valid. The quality of data was assured by internal validation and
cost effectiveness increased substantially. Even though reduction is
not accompanied to refinement per se, the present study shows
examples of synergy between the two Rs, noted in a project related
to decreased group size due to high pregnancy rate, as a result of
high quality animal welfare. In addition, the new micro-sampling
technique resulted in a reduced number of utilized rats and mice,
but also in substantially reduced discomfort at blood sampling as
compared to the technique for larger volumes samples [33,34].
Also, the micro-sampling resulted in higher scientific quality with
simultaneous evaluation of toxicity and toxicokinetic information.
From pharmaceutical industry and beyond
Several arguments support that the strategies identified in the
present study might be transferred outside the context of a
pharmacological industry. Firstly, the constant pressure to
minimize the use of laboratory animals is considerable throughout
the whole biomedical sector, and for the safety assessment area in
specific. Subsequently, the demands from legislations such as
REACH and the new EU-directive for laboratory animals are
related to other chemical products and any use of animals [4].
There is also a need to further advances and harmonisation of the
3Rs in different regulatory sectors [35]. In addition, the initiatives
to implement new methods (e.g. the successful implementation of
Figure 4. Projects linked to the department ownership (a) or the participation (b) of each project. The number of projects specified
according to category of the project (a) and specified in relation to the participation in projects with multiple or single departments (b).
doi:10.1371/journal.pone.0101638.g004
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micro-sampling in this study) can be used in many different types
of investigative and regulatory experiments. Methodological
interventions, as compared to improved study design and
coordination, are also most likely to be transferrable into other
research areas within Life Science. A similar retrospective survey
was previously performed in a medium-sized pharmaceutical
company [36], where the ratio of animal use per compound
synthetized showed a decrease with 80% as measured over 12
years (1991–2002). This reduction coincided with introduction of
various in vitro screening tests, indicating a causal relation. No
further analyses on how the reduction was achieved in more detail
were, however, presented. Further, systematic coordination can be
applied in any organization. Despite this, it might be more difficult
to implement these strategies in scattered organizations, such as
academia or sub-contracted contract research organizations
(CROs). Also, the resources to validate innovative methods and
new study designs is often limited in non-industrial organizations
in which the economic efficiency derived through reduction
cannot be directly exploited. Previous examples of successful 3R
initiatives in toxicity testing have been variously reported from
different areas of endeavor, but have often been very focused on
particular tests and use areas. It has, for example, been shown that
regulatory requirements of acute toxicity testing of pharmaceuti-
cals can be replaced as acceptable supporting information can be
achieved from single high dose toxicity studies [37]. One of the
most influential general reports on this subject is the OECD list of
thirty 3R-improved or up-dated tests for short- and long-term
toxicity testing, complete with description of the 3R relevance and
changes made (Table available for download at http://www.oecd.
org/env/ehs/testing/44146476.pdf). For example, the first alter-
native to the conventional acute toxicity test (TG401) is the revised
version of TG420, adopted in 2001. This is an example of a new
study design with fixed doses and testing in one sex only (usually
females). Another example of study design improvement is the
recent revision of the OECD guideline for bioaccumulation tests in
fish, resulting in a reduction with approximately 30% [38]. In
summary, the international development of validated and
recognized methods and study designs is important, but suffers
from the time-consuming process before acceptance within the
OECD framework. Other reports of reduction are sporadic in the
literature and do not bear any concerted efforts across a whole
safety testing strategy. In the present study, all 3R-projects were
devised, internally validated and approved before implementation.
To ensure the scientific quality of the data generated after the
implementation of the reduction, a proper validation must be
performed concerning prediction/translation, statistical power and
working situation for personnel and animals etc. As validation is a
crucial step, the European Union Reference Laboratory for
Alternatives to Animal Testing (EURL-ECVAM) has organized a
network of validation laboratories [39]. This is certainly an
important initiative to counterstrike the lack of international
resources for validation. However, in the present study we are able
to show the importance of internal validation and rapid
implementation within an area framed with strict regulations
(i.e. pharmaceutical industry). In fact, four of the projects related
to improved study design, (combining studies and changing dosing
routine; No 2, 3, 5 and 6 in table 1) resulted from reinterpretation
of regulatory guidelines, but with sustained delivery of scientific
information.
In conclusion, it is evident from this study that substantial
reductions in animal use in research can be achieved by different
strategies, including improved study design, method development
and project coordination. Major animal savings were shown in
both regulatory and investigative safety studies. If a similar (i.e.
53%) reduction had been achieved simultaneously within the
twelve largest pharmaceutical companies, the equivalent reduction
world-wide would be about 150,000 rats annually, assuming that
the use of laboratory animals is proportional to their respective
economic turnovers. The work points at the importance of a
strong 3R culture, within the organization, with scientific
engagement, collaboration and a responsive management being
vital components. Based on the results from this study we
recommend a strong commitment in leadership for the 3R to be
translated into cross-department and inter-profession involvement
in projects for innovation, validation and implementation. We also
observe clear examples of synergies between all the three Rs and
conclude that in silico-, in vitro- and in vivo-methods all hold the
potential for applying the reduction R and should be consequently
coordinated at a strategic level.
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